Propanc Biopharma Inc. Common Stock (PPCB)

FairStock Score: 39/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, Propanc trades at $0.41 with a $2.6M market cap. This is a development-stage biopharma with two employees, no approved product, and a lead candidate, PRP, that has only completed pre-clinical studies. Filed figures show revenue was n/a in FY2024, FY2025, and FY2026, while net losses were $1.8M, $58.9M, and $18.9M. In fiscal Q3 2026, the quarter ended 2026-03-31, the net loss was $6.4M; fiscal Q2 2026 lost $3.1M; fiscal Q1 2026 lost $4.8M. That is not a business yet; it is a science project funded by shareholders. Financial health is poor. Trailing free cash flow is -$4.1M, and the FairStock FCF yield is -157.5%. FairStock also calculates ROE of -161.86%, ROCE of -70.14%, Piotroski F-Score of 2/9, and Altman Z-Score of -12.91. The low D/E of 0.05 is little comfort when there is no revenue and cash burn is heavy. The supplied Lynch category is none, because the company lost money in each of the last four years. Valuation looks superficially deep: FairStock P/B is 0.04 and Graham Number is $398.64, implying a 99.90% margin of safety. But Graham would demand earning power and asset protection; with no revenue, negative earnings, and a $2.6M market cap, those ratios may be artifacts. A beta of 3.33 and a 52-week range of $0.09-$6.79 confirm extreme volatility. The annual loss narrowed from $58.9M in FY2025 to $18.9M in FY2026, which is progress, but PRP must still advance through trials, approvals, and financing. Until then, the moat is nonexistent and the equity is speculative.

In plain English: Propanc Biopharma is a tiny development-stage company trying to create cancer treatments, but it has no product on the market and reports no revenue. It has lost money for years, including an $18.9 million loss in fiscal 2026, so the business looks very weak financially. Its $0.41 share price may look low versus some accounting measures, but without sales or profits it is hard to call it genuinely cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer